An Environmental Risk Assessment (ERA) for pharmaceuticals is a scientific evaluation of the potential environmental impact of pharmaceutical substances and their metabolites. It analyzes how pharmaceuticals behave in the environment after use, particularly in water, soil and on plants or animals. The aim is to identify risks to the environment at an early stage and to develop appropriate risk reduction measures.

In connection with the Market Authorization Application (MAA), which is required for the approval of a pharmaceutical, an ERA must be carried out and documented. This assessment helps the regulatory authorities to decide whether a pharmaceutical can be placed on the market without negative effects on the environment.

The Market Authorization Application (MAA) is the application that a company submits to the competent regulatory authorities in order to place a pharmaceutical on the market. Numerous scientific data must be submitted for the authorization of a pharmaceutical, including a comprehensive Environmental Risk Assessment (ERA).

The ERA is an essential part of the MAA, as the regulatory authorities (such as the EMA in the EU) must ensure that the pharmaceutical has no harmful effects on the environment. Without a complete ERA, the marketing authorization application cannot be successfully completed.

The MAA contains all the necessary information on the safety, efficacy and quality of a pharmaceutical. The ERA ensures that the environmental risks of the pharmaceutical are also taken into account. Only if all requirements are met - including the ERA - can the pharmaceutical be considered for marketing authorization.

Pharmaceuticals can enter the environment after use via wastewater, agricultural use or improper disposal. As many pharmaceutical substances remain biologically active, they can have unintended effects on ecosystems, aquatic life and even human health. An ERA helps to assess the potential environmental impacts of these pharmaceuticals and develop measures to mitigate them.

In the EU conducting an ERA is mandatory for the approval of new pharmaceuticals. This assessment ensures that pharmaceuticals have no harmful effects on the environment and can therefore be used in a more environmentally friendly and sustainable way.

Additional risk:

Pharmaceutical residues found in water bodies can pose a particular risk to aquatic organisms, as they can act at low concentrations and are often not immediately detectable.

The conduct of an Environmental Risk Assessment (ERA) for pharmaceuticals follows a structured procedure:

1. Data search: first, all relevant information on the chemical properties of the pharmaceutical, such as its persistence in the environment, bioaccumulation and toxicity, is collected. This includes scientific data from studies and information from authorization dossiers.
2. Exposure assessment: The next step is to determine the extent to which the pharmaceutical enters the environment. This involves calculating how much of the pharmaceutical could end up in water, soil or air. This is estimated based on production volumes, use patterns and disposal practices.
3. Impact assessment: The impact of the pharmaceuticals and their metabolites on different environmental systems is analyzed. These assessments include tests on aquatic life, plants and soil organisms to determine the toxicity of the drug.
4. Risk characterization: Finally, the potential environmental risk quotient (PEC/PNEC) is calculated. If this quotient exceeds a certain threshold, additional risk mitigation measures may be required.
5. Reporting: All results of the ERA are documented in a comprehensive report that is submitted to the relevant regulatory authorities.

If the Environmental Risk Assessment (ERA) as part of a Market Authorization Application (MAA) is insufficient, this can lead to a rejection of the marketing authorization application. Regulatory authorities such as the EMA (European Medicines Agency) require a complete and thorough ERA to ensure that the drug has no adverse environmental effects.

Possible consequences of an inadequate ERA:

• Delays in the approval process because additional data or testing is required.
• Rejection of the application or requirements for additional risk mitigation measures, such as changing production methods or the use of the pharmaceutical.

It is therefore crucial to prepare a precise and thorough ERA that meets all relevant regulatory requirements in order to avoid delays and possible rejections.

All pharmaceuticals that are intended for approval in the EU or other large markets must undergo an Environmental Risk Assessment (ERA). This applies to both new pharmaceuticals and existing pharmaceuticals with new data or changes in use.

The ERA is particularly important for pharmaceuticals for human use that are used in large quantities or could end up in water. However, veterinary pharmaceuticals or veterinary products also require an ERA if they have the potential to enter the environment, particularly through the disposal of animal waste or through agricultural applications.

The duration of an Environmental Risk Assessment (ERA) for pharmaceuticals can vary depending on the scope and complexity of the assessment. In general, the process takes between 2 and 6 months, depending on the availability of the required data, the type of pharmaceutical and the regulatory requirements of the respective market.

For pharmaceuticals based on an existing dossier, the process can be completed more quickly. However, new pharmaceuticals with many unknown environmental effects require more comprehensive studies and detailed analysis.

Our experts at CSB Compliance do everything they can to make the ERA as efficient and smooth as possible without compromising quality or regulatory requirements.

CSB Compliance supports companies in carrying out a complete and legally compliant Environmental Risk Assessment (ERA) for pharmaceuticals. Our experienced team of experts offers you:

• Advice on data collection and evaluation: we will help you identify and evaluate the relevant data required for the ERA.
• Exposure assessment and risk calculations: We use our sophisticated models and tools to calculate the exposure of your pharmaceuticals and their impact on the environment.
• Preparation of ERA reports: We produce detailed reports that meet regulatory requirements and help you obtain authorization from the competent authorities.
• Regulatory support: We assist you in communicating with authorities and ensure that all requirements are met on time and in full.

Our approach combines scientific precision with practical experience to ensure that you go through the ERA process efficiently and safely.